Lenvatinib and Pembrolizumab Combination Therapy In HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal, and/or Pulmonary Involvement
Conditions: Human Papilloma Virus; Recurrent Respiratory Papillomatosis Interventions: Drug: Lenvatinib; Drug: Pembrolizumab Sponsors: Massachusetts General Hospital; Eisai Inc.; Merck Sharp & Dohme Corp. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 27, 2020 Category: Research Source Type: clinical trials
Lenvatinib and Pembrolizumab In HPV-associated RRP
Conditions: Human Papilloma Virus; Recurrent Respiratory Papillomatosis Interventions: Drug: Lenvatinib; Drug: Pembrolizumab Sponsors: Massachusetts General Hospital; Eisai Inc.; Merck Sharp & Dohme Corp. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 26, 2020 Category: Research Source Type: clinical trials
INOVIO Receives Orphan Drug Designation From U.S. FDA for DNA Medicine INO-3107 To Treat Rare Disease Recurrent Respiratory Papillomatosis (RRP)
PLYMOUTH MEETING, Pa., July 29, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO) today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for INO-3107, its DNA medicine being evaluated in a Phase 1/2 trial for... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 29, 2020 Category: Pharmaceuticals Source Type: clinical trials
INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)
Condition: Respiratory Papillomatosis Interventions: Drug: INO-3107; Device: CELLECTRA™ 2000 Sponsor: Inovio Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 22, 2020 Category: Research Source Type: clinical trials
